Delving into the Latest Updates on TV-10 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious Diseases

Active Indication-

Inactive Indication

Gram-Negative Bacterial Infections

Originator Organization

BKG Pharma ApS

Active Organization-

Inactive Organization

BKG Pharma ApS

License Organization-

Drug Highest PhaseDiscontinuedPreclinical

First Approval Date-

Regulation-

AbstractThis study aimed to investigate the impact of administration routes in establishing the Adriamycin (ADR)‐induced chronic kidney disease (CKD) model. Using BALB/c mice, we compared the effects of conventional tail‐vein injection (TV10, 10 mg/kg) to those of retro‐orbital sinus (orbital vein) injection (OV10, 10 mg/kg; OV8, 8 mg/kg). The results indicated that the OV10 group exhibited CKD pathology similar to the TV10 group, with both groups demonstrating significantly higher urinary albumin/creatinine ratio (p < 0.05), tubular injury (p < 0.05), and degree of renal fibrosis (p < 0.05) than the OV8 group. No significant differences were observed between the OV10 and TV10 groups in urinary albumin/creatinine ratio, tubular injury, and degree of renal fibrosis. These findings demonstrated that retro‐orbital administration of 10 mg/kg ADR induces comparable effects to conventional tail‐vein administration. This technique's technical simplicity may improve experimental efficiency, reproducibility, and animal welfare in CKD research. In conclusion, this study validates the utility of retro‐orbital injection in CKD model establishment, demonstrating its potential to standardize and improve the reliability of future CKD research protocols.

100 Deals associated with TV-10

Login to view more data